Drugs / VIR-5525
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06960395 | Jul 2025 → Aug 2029 expected | — | Vir Biotechnology, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-07-24 | Vir Biotechnology, Inc. | Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors vir.bio ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIR-5525 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06960395 ↗ |
| Route | Intravenous | “Route of Administration: Intravenous (IV) infusion” NCT06960395 ↗ |